F S&P 500
5,565.75 +19.75 (+0.36%) F Dow Jones
39,584.00 +34.00 (+0.09%) F Nasdaq
20,125.25 +85.75 (+0.43%) E-mini Russell 2000 Index Futur
2,072.10 +12.00 (+0.58%) Petróleo
82.56 +0.82 (+1.00%) Oro
2,340.00 +3.40 (+0.15%)
Sandoz Group AG (SDZ.SW)
Sandoz Group AG
Forum 1
Novartis Campus
Basel 4056
Switzerland
41 61 324 11 11
https://www.sandoz.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 22,633
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Richard Saynor | Chief Executive Officer | 1.8M | N/D | 1967 |
| Mr. Colin Michael Bond | Chief Financial Officer | N/D | N/D | 1960 |
| Mr. Asaf Gal | Chief Technology Officer | N/D | N/D | 1969 |
| Ms. Claire D'Abreu-Hayling | Chief Scientific Officer | N/D | N/D | 1964 |
| Ms. Karen M. King | Head Global Investor Relations | N/D | N/D | N/D |
| Ms. Ingrid Sollerer | General Counsel & Chief Compliance Officer | N/D | N/D | 1974 |
| Ms. Tripti Jha | Chief People Officer | N/D | N/D | 1977 |
| Mr. Francisco Ballester | President of International | N/D | N/D | 1961 |
| Mr. Pierre Bourdage | Chief Commercial Officer | N/D | N/D | 1979 |
| Dr. Glenn A. Gerecke Ph.D. | Chief Manufacturing & Supply Officer | N/D | N/D | 1959 |
Descripción
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Gestión corporativa
La calificación ISS Governance QuickScore de Sandoz Group AG a partir del 1 de junio de 2024 es 3. Las puntuaciones principales son Auditoría: 6; Junta: 4; Derechos del accionista: 9; Compensación: 2.
